WO2002011711A3 - Formulations of mometasone and a bronchodilator for pulmonary administration - Google Patents

Formulations of mometasone and a bronchodilator for pulmonary administration Download PDF

Info

Publication number
WO2002011711A3
WO2002011711A3 PCT/US2001/024093 US0124093W WO0211711A3 WO 2002011711 A3 WO2002011711 A3 WO 2002011711A3 US 0124093 W US0124093 W US 0124093W WO 0211711 A3 WO0211711 A3 WO 0211711A3
Authority
WO
WIPO (PCT)
Prior art keywords
bronchodilator
formulations
mometasone
pulmonary administration
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/024093
Other languages
French (fr)
Other versions
WO2002011711A2 (en
WO2002011711B1 (en
Inventor
Leonard W Kaplan
Karl P Weinrich
Theodore L Iorio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longwood Pharmaceutical Research Inc
Original Assignee
Longwood Pharmaceutical Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longwood Pharmaceutical Research Inc filed Critical Longwood Pharmaceutical Research Inc
Priority to EP01956079A priority Critical patent/EP1311294A2/en
Priority to AU2001278115A priority patent/AU2001278115A1/en
Priority to CA002417973A priority patent/CA2417973A1/en
Publication of WO2002011711A2 publication Critical patent/WO2002011711A2/en
Anticipated expiration legal-status Critical
Publication of WO2002011711A3 publication Critical patent/WO2002011711A3/en
Publication of WO2002011711B1 publication Critical patent/WO2002011711B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical formulation is provided for pulmonary drug administration of a bronchodilator, a corticosteroid and an optional pharmaceutically acceptable carrier. In addition, methods for using the formulation to treat bronchodilator/corticosteroid-reponsive conditions, diseases or disorders are provided, as are drug delivery devices and dosage forms for housing and/or dispensing the formulations.
PCT/US2001/024093 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration Ceased WO2002011711A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01956079A EP1311294A2 (en) 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration
AU2001278115A AU2001278115A1 (en) 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration
CA002417973A CA2417973A1 (en) 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22354100P 2000-08-04 2000-08-04
US60/223,541 2000-08-04

Publications (3)

Publication Number Publication Date
WO2002011711A2 WO2002011711A2 (en) 2002-02-14
WO2002011711A3 true WO2002011711A3 (en) 2003-02-27
WO2002011711B1 WO2002011711B1 (en) 2004-04-22

Family

ID=22836952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024093 Ceased WO2002011711A2 (en) 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration

Country Status (5)

Country Link
US (2) US20020076382A1 (en)
EP (1) EP1311294A2 (en)
AU (1) AU2001278115A1 (en)
CA (1) CA2417973A1 (en)
WO (1) WO2002011711A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
WO2003013547A1 (en) * 2001-08-07 2003-02-20 Galephar M/F Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1501479A1 (en) * 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
TR200201343A2 (en) * 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Pharmaceutical composition containing corticosteroid and antiseptic
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003258971B2 (en) * 2002-06-27 2010-06-17 Novartis Ag Device and method for controlling the flow of a powder
WO2004018025A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
DK1542904T3 (en) 2002-08-27 2008-04-21 Schering Corp Process for preparing formulations for a metered dose inhaler
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
CN101265226B (en) 2003-05-22 2013-04-24 联合治疗公司 Compounds and methods for delivery of prostacyclin analogs
SE526850C2 (en) * 2003-06-19 2005-11-08 Microdrug Ag Pharmaceutical combined dry powder dose separated on common dose bed
SE527069C2 (en) 2003-06-19 2005-12-13 Mederio Ag Method and apparatus for administering drug powder
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
KR20060106823A (en) * 2003-10-20 2006-10-12 쉐링 코포레이션 Pharmaceutical aerosol compositions
NZ552869A (en) * 2004-07-02 2010-06-25 Boehringer Ingelheim Int Aerosol suspension formulations containing TG 227 ea as a propellant, an ipratropium or tiotropium salt and a small amount of free water to stabilise the composition
EA200700600A1 (en) * 2004-09-09 2008-02-28 Сипла Лимитед PHARMACEUTICAL COMPOSITION CONTAINING BETUMEPHOLIC AGENT AND ANTI-CHOLINERGIC AGENT
DK2377557T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
RU2440972C2 (en) * 2004-12-17 2012-01-27 Сипла Лимитед Crystalline levosalbutamol sulfate, method of its obtaining and pharmaceutical composition, which contains it
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
DE102006017320A1 (en) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
EP1844805A1 (en) * 2006-04-13 2007-10-17 Boehringer Ingelheim Pharma GmbH & Co.KG Inhaler
GB0616299D0 (en) * 2006-08-16 2006-09-27 Cambridge Consultants Drug Capsules for dry power inhalers
JP5570996B2 (en) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド Delivery of aerosolizable foodstuffs
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2012058719A1 (en) * 2010-11-02 2012-05-10 The Universtity Of Sydney Inhalable compositions
US20140011784A1 (en) * 2011-11-17 2014-01-09 Jonathan Matz Method and composition for treating asthma
KR101342199B1 (en) 2012-02-27 2013-12-16 전진우 Capsule type injector assembly
US20150335695A1 (en) * 2014-05-25 2015-11-26 Tu Song-Anh Nguyen Therapeutic Nutritional Supplement to Alleviate Symptoms of COPD and Delay the Progression Thereof
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017146994A1 (en) * 2016-02-24 2017-08-31 Merck Sharp & Dohme Corp. Controlled agglomeration of micronized drug or drug-excipient mixtures

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030604A (en) * 1997-01-20 2000-02-29 Astra Aktiebolag Formulation for inhalation
WO2000051591A1 (en) * 1999-03-03 2000-09-08 Novartis Ag Combinations of formoterol and mometasone furoate for asthma
WO2000053187A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
WO2001078744A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and mometasone
WO2001078740A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising mometasone and salmeterol
WO2002005784A1 (en) * 2000-07-17 2002-01-24 Aeropharm Technology, Inc. A medicinal aerosol formulation
EP1201242A2 (en) * 1994-01-27 2002-05-02 Schering Corporation Use of mometasone furoate in an adjuvant therapy
WO2002049616A1 (en) * 2000-12-19 2002-06-27 Astrazeneca Ab Pharmaceutical aerosol formulation
EP1236467A1 (en) * 2001-03-02 2002-09-04 Chemo Healthcare S.A. Inhalatory compositions of formoterol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE8790T1 (en) * 1981-02-02 1984-08-15 Schering Corporation AROMATIC HETEROCYCLIC STEROID ESTER, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR890000664B1 (en) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 Preparation method for micronised be clomethasone dispropionate mono-hydrate
US5126133A (en) * 1989-06-27 1992-06-30 Mycogen Corporation Bacillus thuringiensis isolate active against lepidopteran pests, and genes encoding novel lepidopteran-active toxins
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
PT101988B (en) * 1997-04-04 2004-02-27 Hovione Farmaciencia Sa SYSTEM OF ORIENTATION AND POSITIONING OF AN OBJECT
US5837399A (en) * 1997-07-22 1998-11-17 Hughes Electronics Corporation Through-wall electrical terminal and energy storage cell utilizing the terminal

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201242A2 (en) * 1994-01-27 2002-05-02 Schering Corporation Use of mometasone furoate in an adjuvant therapy
US6030604A (en) * 1997-01-20 2000-02-29 Astra Aktiebolag Formulation for inhalation
WO2000051591A1 (en) * 1999-03-03 2000-09-08 Novartis Ag Combinations of formoterol and mometasone furoate for asthma
WO2000053187A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
WO2001078744A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and mometasone
WO2001078740A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising mometasone and salmeterol
WO2002005784A1 (en) * 2000-07-17 2002-01-24 Aeropharm Technology, Inc. A medicinal aerosol formulation
WO2002049616A1 (en) * 2000-12-19 2002-06-27 Astrazeneca Ab Pharmaceutical aerosol formulation
EP1236467A1 (en) * 2001-03-02 2002-09-04 Chemo Healthcare S.A. Inhalatory compositions of formoterol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1311294A2 *

Also Published As

Publication number Publication date
EP1311294A2 (en) 2003-05-21
AU2001278115A1 (en) 2002-02-18
WO2002011711A2 (en) 2002-02-14
CA2417973A1 (en) 2002-02-14
US20040198708A1 (en) 2004-10-07
WO2002011711B1 (en) 2004-04-22
US20020076382A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
WO2004105731A8 (en) Nasal formulations including a topical decongestant and a topical corticosteroid and their use in treatment of obstructive sleep apnea
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2005046640A3 (en) Multi-site drug delivery platform
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
CA2388610A1 (en) Oral transmucosal drug dosage using solid solution
WO2001062227A3 (en) Anticholinergic drug formulations for treatment of chronic obstr uctive pulmonary disease
BR0108730A (en) System, device and method for administering a drug, mouthpiece of a drug delivery device, device for administering multiple unit doses of a drug, methods for preparing a drug delivery system and a drug formulation and for treatment of a patient who needs multiple doses of a drug, drug formulation and multiparticulates
EP3154515B1 (en) Improvements to nasal compositions and method of use thereof
WO2006113505A3 (en) Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP1275381A4 (en) Time-release coated solid compositions for oral administration
WO2003032928A3 (en) Therapeutic composition and use
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
EP0966966A3 (en) Nefazodone dosage form
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2001041742A3 (en) Antiviral medication
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2002024203A3 (en) Controlled release formulations for oral administration
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
MXPA03010672A (en) Therapeutic compositions for repairing chondropathy.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2417973

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001956079

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001956079

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

B Later publication of amended claims

Effective date: 20030110

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001956079

Country of ref document: EP